Skip to Content
  • Revenues ($M)
    $16,560
  • Revenue Percent Change
    4.3%
  • Profits ($M)
    $1,565
  • Profits Percent Change
    -21.9%
  • Assets ($M)
    $31,748
  • Employees
    25,000
  • Market Value — as of March 31, 2016 ($M)
    $106,848
  • Previous Rank
    195
  • Morning Consult Brand Index
    B+

The biopharmaceutical company manufactures medicines for Alzheimer’s, dementia, pyschiatric disorders, cardiovascular, diabetes, oncology, and hepatitis.

Company Info

CEO
Giovanni Caforio
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
New York, NY
Websitehttp://www.bms.com
Years on Fortune 500 List22
Employees25,000
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$16,5604.3%
Profits ($M)$1,565-21.9%
Assets ($M)$31,748-
Total Stockholder Equity ($M)$14,266-
Market Value — as of March 31, 2016 ($M)$106,848-

Profit Ratios

Profit as % of Revenues9.5%
Profits as % of Assets4.9%
Profits as % of Stockholder Equity11%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)0.93
EPS % Change (from 2014)-22.5%
EPS % Change (5 year annual rate)-12.3%
EPS % Change (10 year annual rate)-4.8%

Total Return

Total Return to Investors (2015)19.3%
Total Return to Investors (5 year, annualized)25.2%
Total Return to Investors (10 year, annualized)16.4%